Price Band
₹96 - ₹101
Lot Size
1200
Issue Size
₹29.75 Cr
GMP
N/A
Subscription
7.67x
Analyzing...
IPO Schedule
1
Open
14 May 2025
2
Close
16 May 2025
3
Allotment
-
4
Listing
21 May 2025
About Accretion Pharmaceuticals
Accretion Pharmaceuticals is an SME focused on manufacturing and marketing pharmaceutical formulations. They operate primarily within the domestic market, supplying a range of therapeutic products.
Key Strengths
- High Return on Equity (ROE) of 72.47% indicates efficient use of shareholder equity and strong profitability.
- Relatively moderate Price to Earnings (P/E) ratio of 21.29, potentially indicating reasonable valuation compared to industry peers (requires further peer comparison).
- Focus on pharmaceutical formulations provides a stable and essential product offering.
- SME segment listing provides access to capital markets for growth and expansion.
- Established presence in the domestic pharmaceutical market.
Risk Factors
- •SME segment listing carries inherent risks associated with smaller companies, including limited financial resources and operational scale.
- •Pharmaceutical industry is highly regulated and competitive, requiring continuous investment in R&D and marketing.
- •Dependence on domestic market exposes the company to local economic conditions and regulatory changes.
Valuation Analysis
The IPO appears reasonably valued based on the P/E ratio, but a comprehensive valuation analysis should consider comparable companies and future growth prospects. The high ROE is a positive indicator, warranting further investigation of the company's competitive advantages.
IPO Details
ExchangeNSE
SegmentSME
ISININE0T8T01010
NSE SymbolACCPL
Face Value₹10
Lot Size1200
Issue Size₹29.75 Cr
Key Metrics
ROE72.47%
ROCE36.73%
P/E Ratio21.29
Industry P/E20
EPS4.74
PAT Margin11.51%
Debt/Equity2.52
Growth & Quality
ProfitableYes ✓
Subscription
Total1.12x
Documents
RHP not available
Key Dates
Open Date14 May 2025
Close Date16 May 2025
Listing21 May 2025